Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2021 Feb 3;48(9):2737–2748. doi: 10.1007/s00259-021-05216-3

Fig. 3.

Fig. 3

The radioactive biodistribution (Bio-D) of IR800/89Zr dual-labeled ICAM-1 monoclonal antibody ([89Zr]Zr-DFO-ICAM-1-IR800) or IgG control ([89Zr]Zr-DFO-IgG-IR800) in the tumors and major organs of subcutaneous or orthotopic pancreatic ductal adenocarcinoma (PDAC) models (BxPC-3 and AsPC-1). p < 0.05. Groups: IR800/89Zr dual-labeled ICAM-1 monoclonal antibody ([89Zr]Zr-DFO-ICAM-1-IR800) injected into subcutaneous BxPC-3 models (Group 1; n = 4); [89Zr]Zr-DFO-ICAM-1-IR800 injected into subcutaneous AsPC-1 models (Group 2; n = 5); IR800/89Zr dual-labeled IgG isotype control ([89Zr]Zr-DFO-IgG-IR800) injected into subcutaneous BxPC-3 models (Group 3; n = 5); [89Zr]Zr-DFO-ICAM-1-IR800 injected into orthotopic BxPC-3 models (Group 4; n = 3)